Publications by authors named "Christopher W Schneider"

Radiation therapy is essential in both curative and palliative treatments for most cancers. However, traditional radiation therapy workflows using computed tomography (CT) simulation-based planning and cone beam CT image guidance face several technical challenges, including limited tumor visibility and daily fluctuations in tumor size and shape. Magnetic resonance imaging (MRI) guided linear accelerators (MR-Linacs) address these issues by enabling precise visualization of changes in tumor position and morphologic changes, as well as changes in surrounding organs-at-risk.

View Article and Find Full Text PDF

The purpose of this Medical Physics Practice Guideline (MPPG) is to describe the minimum level of medical physics support deemed prudent for the practice of linear-accelerator, photon-based (linac) stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT) services. This report is an update of MPPG 9.a published in 2017.

View Article and Find Full Text PDF

Background: Pulsed field ablation (PFA) has proven to be at least noninferior to thermal ablation for paroxysmal atrial fibrillation (AF). Predictors of AF freedom for PFA have not yet been described.

Objective: The purpose of this study was to identify clinical and procedural predictors of treatment success in paroxysmal AF patients treated with the pentaspline PFA catheter.

View Article and Find Full Text PDF

Background: Autonomic denervation is an ancillary phenomenon during thermal ablation of atrial fibrillation (AF), that may have synergistic effects on symptomatic improvement and long-term freedom from AF. Pulsed field ablation (PFA), a nonthermal ablation modality, was noninferior to thermal ablation in treating AF; however, PFA's relative myocardial selectivity may minimize autonomic effects.

Objectives: This study sought to compare heart rate (HR) and heart rate variability (HRV) metrics as markers of autonomic function after ablation using PFA vs thermal ablation.

View Article and Find Full Text PDF

Background: The ADVENT randomized trial revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal (radiofrequency/cryoballoon) and pulsed field ablation (PFA). However, recent studies indicate that the postablation AA burden is a better predictor of clinical outcomes than the dichotomous endpoint of 30-second AA recurrence.

Objectives: The goal of this study was to determine: 1) the impact of postablation AA burden on outcomes; and 2) the effect of ablation modality on AA burden.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the risk of silent cerebral events (SCE) and silent cerebral lesions (SCL) associated with two types of atrial fibrillation (AF) ablation: pulsed field ablation (PFA) and standard thermal ablation, focusing on potential long-term effects on brain health.
  • - A total of 77 patients underwent randomized treatment across six centers, with follow-up MRIs conducted 12-48 hours post-procedure. Results showed low rates of SCE/SCL, with some findings confirmed by a blinded imaging laboratory.
  • - Both ablation methods demonstrated minimal neurological complications, with no significant differences in outcomes, suggesting that both PFA and thermal ablation involve a low risk of silent cerebral
View Article and Find Full Text PDF
Article Synopsis
  • The BEAT PAROX-AF trial is a European study comparing pulsed field ablation (PFA) with radiofrequency (RF) ablation for treating drug-resistant paroxysmal atrial fibrillation (AF), focusing on efficacy and safety.
  • A total of 292 participants were randomly assigned to either PFA or RF using specific protocols to measure outcomes such as the recurrence of atrial arrhythmia and serious adverse events.
  • The study began in December 2021 and will conclude recruitment in January 2024, with results expected to be published in mid-2025, aiming to improve treatment strategies for patients with paroxysmal AF.
View Article and Find Full Text PDF

Background: Pulsed-field ablation (PFA) is a novel nonthermal ablation technology with high procedural safety and efficiency for pulmonary vein isolation (PVI). Premarket data showed high PVI durability during mandatory remapping studies. Data on lesion durability in real-world patients with clinically indicated redo procedures are scarce.

View Article and Find Full Text PDF

Aims: When it occurs, pulmonary vein (PV) stenosis after atrial fibrillation (AF) ablation is associated with significant morbidity. Even mild-to-moderate PV narrowing may have long-term implications. Unlike thermal ablation energies, such as radiofrequency (RF) or cryothermy, pulsed field ablation (PFA) is a non-thermal modality associated with less fibrotic proliferation.

View Article and Find Full Text PDF

Background: Catheter-based pulmonary vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation, which delivers microsecond high-voltage electrical fields, may limit damage to tissues outside the myocardium. The efficacy and safety of pulsed field ablation as compared with conventional thermal ablation are not known.

View Article and Find Full Text PDF

Aims: Pulsed field ablation (PFA) is a new, non-thermal ablation modality for pulmonary vein (PV) isolation in patients with atrial fibrillation (AF). The multi-centre EUropean Real World Outcomes with Pulsed Field AblatiOn in Patients with Symptomatic AtRIAl Fibrillation (EU-PORIA) registry sought to determine the safety, efficacy, and learning curve characteristics for the pentaspline, multi-electrode PFA catheter.

Methods And Results: All-comer AF patients from seven high-volume centres were consecutively enrolled.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness and safety of pulsed field ablation (PFA) compared to traditional thermal ablation methods (radiofrequency or cryoballoon) in treating drug-resistant paroxysmal atrial fibrillation (PAF).
  • - Conducted as a randomized controlled trial, it follows patients for 12 months to evaluate outcomes based on the success of the procedure and any recurrence of arrhythmia or complications.
  • - The research aims to provide scientific evidence on whether the pentaspline PFA catheter can offer noninferior results in terms of procedural efficacy and safety compared to standard thermal ablation techniques.
View Article and Find Full Text PDF

Background: The unique tissue selectivity of pulsed field ablation (PFA) allows for minimizing collateral damage to the nerves/esophagus. However, the safety profile of epicardial PFA on coronary arteries (CAs) has not been well defined.

Objectives: This study sought to evaluate the effect of epicardial PFA directly on CAs in a swine model.

View Article and Find Full Text PDF

Background: Pulsed field ablation (PFA) has recently been shown to penetrate ischemic scar, but details on its efficacy, risk of arrhythmias, and imaging insights are lacking. In a porcine model of myocardial scar, we studied the ability of ventricular PFA to penetrate scarred tissue, induce ventricular arrhythmias, and assess the influence of QRS gating during pulse delivery.

Methods: Of a total of 6 swine, 5 underwent coronary occlusion and 1 underwent radiofrequency ablation to create infarct scar and iatrogenic scar models, respectively.

View Article and Find Full Text PDF

Purpose: Photon radiotherapy techniques typically devote considerable attention to limiting the exposure of healthy tissues outside of the target volume. Numerous studies have shown, however, that commercial treatment planning systems (TPSs) significantly underestimate the absorbed dose outside of the treatment field. The purpose of this study was to test the feasibility of quickly and accurately calculating the total absorbed dose to the whole body from photon radiotherapy in individual patients.

View Article and Find Full Text PDF

A burgeoning population of cancer survivors is at risk of late health effects following radiation therapy including second cancers, with the majority of these cancers occurring outside of the treatment volume of the primary cancer. Commercial radiotherapy treatment planning systems underestimate the out-of-field dose. Previous analytical models of out-of-field dose have assumed radial symmetry and/or approximated the dimensions of collimators as semi-infinite planes.

View Article and Find Full Text PDF

Purpose: Modern radiotherapy practices typically report the absorbed dose (D) within the 5% relative isodose volume (i.e., the therapeutic dose region) to an accuracy of 3%-5%.

View Article and Find Full Text PDF

Purpose: To develop a simple model of therapeutic and stray absorbed dose for a variety of treatment machines and techniques without relying on proprietary machine-specific parameters.

Methods: Dosimetry measurements conducted in this study and from the literature were used to develop an analytical model of absorbed dose from a variety of treatment machines and techniques in the 6 to 25 MV interval. A modified one-dimensional gamma-index analysis was performed to evaluate dosimetric accuracy of the model on an independent dataset consisting of measured dose profiles from seven treatment units spanning four manufacturers.

View Article and Find Full Text PDF

Background And Aim Of The Study: Percutaneous catheter-based mitral annuloplasty (PTMA) exploits the anatomic proximity of the coronary sinus (CS) to the mitral valve apparatus. Acute results of PTMA have been favorable, but the durability of the geometric alterations associated with PTMA has not been reported. The study aim was to assess the three-dimensional (3D) geometry of the mitral annulus (MA) in normal sheep at 20 weeks after PTMA implantation.

View Article and Find Full Text PDF